|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US6555339B1
(en)
*
|
1997-04-14 |
2003-04-29 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated human protein-coupled receptors
|
|
US20030017528A1
(en)
|
1998-11-20 |
2003-01-23 |
Ruoping Chen |
Human orphan G protein-coupled receptors
|
|
ATE301673T1
(de)
*
|
1998-11-20 |
2005-08-15 |
Arena Pharm Inc |
Menschliche, an ein g-protein gekoppelter rezeptor rup3 ohne bekannten ligand
|
|
US7816492B2
(en)
*
|
1998-11-20 |
2010-10-19 |
Arena Pharmaceuticals, Inc. |
Human G protein-coupled receptors
|
|
USRE42190E1
(en)
|
1998-11-20 |
2011-03-01 |
Arena Pharmaceuticals, Inc. |
Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
|
|
GB9903767D0
(en)
*
|
1999-02-18 |
1999-04-14 |
Univ Glasgow |
Receptor assay
|
|
EP1235931A2
(en)
*
|
1999-07-30 |
2002-09-04 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
|
|
JP4768946B2
(ja)
*
|
1999-11-17 |
2011-09-07 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
ヒトgタンパク質共役型受容体の内因性および非内因性型
|
|
JP2003518628A
(ja)
*
|
1999-12-10 |
2003-06-10 |
アストラゼネカ アクチボラグ |
化合物
|
|
WO2001044295A2
(en)
*
|
1999-12-17 |
2001-06-21 |
Astrazeneca Ab |
Agonists and antagonists of the receptor gpr19 and their use in appetite control
|
|
EP1255779A2
(en)
*
|
2000-02-18 |
2002-11-13 |
Glaxo Group Limited |
Identification of modulators of gpr41 or gpr42 activity
|
|
GB0003902D0
(en)
*
|
2000-02-18 |
2000-04-05 |
Glaxo Group Ltd |
Assay
|
|
GB0003898D0
(en)
*
|
2000-02-18 |
2000-04-05 |
Glaxo Group Ltd |
Assay
|
|
AU2001241778A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease
|
|
US6436703B1
(en)
*
|
2000-03-31 |
2002-08-20 |
Hyseq, Inc. |
Nucleic acids and polypeptides
|
|
DE60128906T2
(de)
*
|
2000-04-26 |
2008-02-07 |
Sanofi-Aventis Deutschland Gmbh |
Edg8-rezeptor, dessen herstellung und verwendung
|
|
EP1149907A1
(en)
*
|
2000-04-26 |
2001-10-31 |
Aventis Pharma Deutschland GmbH |
EDG8 receptor, its preparation and use
|
|
AU2001250536A1
(en)
*
|
2000-05-03 |
2001-11-12 |
Astrazeneca Ab |
Methods
|
|
AU2001274522A1
(en)
*
|
2000-06-15 |
2001-12-24 |
Takeda Chemical Industries Ltd. |
Novel g protein-coupled receptor protein and dna thereof
|
|
CA2409776A1
(en)
*
|
2000-06-16 |
2001-12-27 |
Incyte Genomics, Inc. |
G-protein coupled receptors
|
|
US7193033B2
(en)
|
2000-06-21 |
2007-03-20 |
Takeda Pharmaceutical Company Limited |
Peptide having appetite stimulating activity
|
|
US20040086940A1
(en)
*
|
2000-07-04 |
2004-05-06 |
Sachio Shibata |
Novel g protein-coupled receptor protein and dna thereof
|
|
AU2002212140A1
(en)
*
|
2000-08-18 |
2002-02-25 |
Novartis Ag |
Inflammation related g-protein coupled receptor
|
|
AU2001286945A1
(en)
*
|
2000-08-30 |
2002-03-13 |
John Hopkins University School Of Medicine |
Identification of activated receptors and ion channels
|
|
WO2001027632A2
(en)
*
|
2000-10-02 |
2001-04-19 |
Biofocus Discovery Limited |
Cellular receptor mutations predicted by multiple-sequence-allignment
|
|
US20040029178A1
(en)
*
|
2000-11-30 |
2004-02-12 |
Yasuko Terao |
Novel g protein-coupled receptor proteins and dnas thereof
|
|
US7241579B2
(en)
|
2000-12-22 |
2007-07-10 |
Smithkline Beecham Corporation |
Method of screening for GPR40 ligands
|
|
GB0031527D0
(en)
*
|
2000-12-22 |
2001-02-07 |
Smithkline Beecham Plc |
New use
|
|
CN1516706A
(zh)
*
|
2001-02-26 |
2004-07-28 |
阿伦纳药品公司 |
人g蛋白偶联受体的内源性和非内源性形式
|
|
US6809104B2
(en)
|
2001-05-04 |
2004-10-26 |
Tularik Inc. |
Fused heterocyclic compounds
|
|
US6919176B2
(en)
*
|
2001-05-07 |
2005-07-19 |
Amgen Inc. |
Polypeptides and nucleic acids associated with cancer
|
|
EP1394543B1
(en)
*
|
2001-05-15 |
2007-08-29 |
Takeda Pharmaceutical Company Limited |
Screening method
|
|
US20020177190A1
(en)
*
|
2001-05-24 |
2002-11-28 |
Yanbin Liang |
Recombinant simian GPR3 receptor
|
|
CA2449553A1
(en)
*
|
2001-06-05 |
2002-12-19 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated versions of plant g protein-coupled receptor: gcr1
|
|
JP2003018992A
(ja)
*
|
2001-06-28 |
2003-01-21 |
Inst Of Physical & Chemical Res |
Pael受容体、Pael受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
|
|
US20050142548A1
(en)
*
|
2001-07-13 |
2005-06-30 |
Thomson Anne M. |
Allelic variants of grp50
|
|
US20030109044A1
(en)
*
|
2001-10-16 |
2003-06-12 |
Millennium Pharmaceuticals, Inc. |
Methods of using 279, a human G protein-coupled protein receptor
|
|
US20030119742A1
(en)
*
|
2001-11-05 |
2003-06-26 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
|
|
US6902902B2
(en)
|
2001-11-27 |
2005-06-07 |
Arena Pharmaceuticals, Inc. |
Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
|
|
JP4360915B2
(ja)
|
2002-01-07 |
2009-11-11 |
ユーロスクリーン・ソシエテ・アノニム |
Gタンパク質共役受容体gpr43のリガンドおよびその使用
|
|
EP1336655A1
(en)
*
|
2002-01-12 |
2003-08-20 |
Aventis Pharma Deutschland GmbH |
Method of identifying protein CAMS (constitutively active mutants)
|
|
WO2003062396A2
(en)
*
|
2002-01-23 |
2003-07-31 |
Arena Pharmaceuticals, Inc. |
Non-endogenous versions of human g protein-coupled receptor: fshr
|
|
EP1471927A2
(en)
*
|
2002-02-06 |
2004-11-03 |
Bayer Aktiengesellschaft |
Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
|
|
US7214495B2
(en)
|
2002-02-14 |
2007-05-08 |
Takeda Pharmaceutical Company Limited |
Screening method
|
|
AU2003218234A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Arena Pharmaceuticals, Inc. |
Methods of expressing non-endogenous g protein coupled receptors in cells
|
|
WO2003104381A2
(en)
*
|
2002-06-08 |
2003-12-18 |
Astrazeneca Ab |
Methods
|
|
CN100473662C
(zh)
*
|
2002-08-01 |
2009-04-01 |
阿瑞那制药公司 |
治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物
|
|
WO2004015426A1
(en)
*
|
2002-08-06 |
2004-02-19 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
|
|
WO2004015427A2
(en)
*
|
2002-08-06 |
2004-02-19 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
|
|
US20060239999A1
(en)
*
|
2002-08-22 |
2006-10-26 |
Mayumi Saki |
Preventive and/or therapeutic drugs for asthma
|
|
WO2004038407A2
(en)
*
|
2002-10-24 |
2004-05-06 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
|
|
US7056685B1
(en)
*
|
2002-11-05 |
2006-06-06 |
Amgen Inc. |
Receptor ligands and methods of modulating receptors
|
|
MXPA05004739A
(es)
|
2002-11-06 |
2005-08-02 |
Tularik Inc |
Compuestos heterociclicos fusionados.
|
|
AU2003277576A1
(en)
|
2002-11-08 |
2004-06-07 |
Takeda Pharmaceutical Company Limited |
Receptor function controlling agent
|
|
US7189524B1
(en)
|
2002-11-25 |
2007-03-13 |
Amgen, Inc. |
Receptor ligands and methods of modulating receptors
|
|
WO2004050853A2
(en)
*
|
2002-12-04 |
2004-06-17 |
Synaptic Pharmaceutical Corporation |
Uses of the snorf55 receptor
|
|
US20040157253A1
(en)
*
|
2003-02-07 |
2004-08-12 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
|
|
US7094572B2
(en)
*
|
2003-03-14 |
2006-08-22 |
Bristol-Myers Squibb |
Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
|
|
WO2004083394A2
(en)
*
|
2003-03-18 |
2004-09-30 |
Arena Pharmaceuticals Inc. |
Human g protein-coupled receptors and modulators thereof for the treatment of inflammatory disorders
|
|
WO2004093912A1
(ja)
*
|
2003-04-23 |
2004-11-04 |
Kyowa Hakko Kogyo Co. Ltd. |
好中球性炎症疾患の予防および/または治療剤
|
|
US20080009551A1
(en)
*
|
2003-04-30 |
2008-01-10 |
Arena Pharmaceuticals, Inc. |
Methods and Compositions for Identifying Modulators of G Protein-Coupled Receptors
|
|
EP1625159B1
(en)
*
|
2003-05-20 |
2011-03-02 |
The University Court Of The University Of Glasgow |
Materials and methods relating to g-protein coupled receptor oligomers
|
|
ATE405827T1
(de)
*
|
2003-09-11 |
2008-09-15 |
Takeda Pharmaceutical |
Screening-verfahren
|
|
CA2544611A1
(en)
*
|
2003-10-09 |
2005-04-21 |
Inverseon, Inc. |
Method of treating airway diseases with beta-adrenergic inverse agonists
|
|
US20070276024A1
(en)
*
|
2003-10-09 |
2007-11-29 |
Inverseon , Inc. |
Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
|
|
WO2005040829A2
(en)
*
|
2003-10-21 |
2005-05-06 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
|
|
WO2005040211A2
(en)
*
|
2003-10-23 |
2005-05-06 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
|
|
WO2005040825A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
|
|
WO2005040828A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
DE602004011400T2
(de)
*
|
2004-01-29 |
2009-01-22 |
Cellzome Ag |
Behandlung von neurodegenerativen krankheiten mit gpr49
|
|
JP2007526917A
(ja)
|
2004-02-20 |
2007-09-20 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
Hm74のオキシデカヒドロナフタレンモジュレーター
|
|
WO2005101005A1
(en)
*
|
2004-04-15 |
2005-10-27 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32)
|
|
US7833722B2
(en)
*
|
2004-04-27 |
2010-11-16 |
Takeda Pharmaceutical Company Limited |
Ligands for G protein-coupled receptor protein and use thereof
|
|
NZ551180A
(en)
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
US7528175B2
(en)
*
|
2004-10-08 |
2009-05-05 |
Inverseon, Inc. |
Method of treating airway diseases with beta-adrenergic inverse agonists
|
|
GB0508988D0
(en)
|
2005-05-03 |
2005-06-08 |
Novartis Ag |
Organic compounds
|
|
US8429755B2
(en)
|
2005-05-26 |
2013-04-23 |
Sandisk Technologies Inc. |
System and method for receiving digital content
|
|
US8673848B2
(en)
|
2012-01-27 |
2014-03-18 |
Novartis Ag |
Synthetic apelin mimetics for the treatment of heart failure
|
|
CN101287832A
(zh)
*
|
2005-10-14 |
2008-10-15 |
艾尼纳制药公司 |
Gpr22和其相关方法
|
|
EP1942724A1
(en)
*
|
2005-11-10 |
2008-07-16 |
Arena Pharmaceuticals, Inc. |
Human g protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto
|
|
GB2456236B8
(en)
|
2007-03-22 |
2009-12-09 |
Heptares Therapeutics Ltd |
Stable muscarinic receptor mutants
|
|
GB0724051D0
(en)
|
2007-12-08 |
2008-01-16 |
Medical Res Council |
Mutant proteins and methods for producing them
|
|
GB0724860D0
(en)
|
2007-12-20 |
2008-01-30 |
Heptares Therapeutics Ltd |
Screening
|
|
GB0802474D0
(en)
|
2008-02-11 |
2008-03-19 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for selecting them
|
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
|
WO2010091692A2
(en)
*
|
2009-04-30 |
2010-08-19 |
H. Lundbeck A/S |
Constitutively active mutants and uses thereof
|
|
GB0910725D0
(en)
|
2009-06-22 |
2009-08-05 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for producing them
|
|
AU2010292172A1
(en)
|
2009-09-09 |
2012-05-03 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
CA3220104A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
JP5804341B2
(ja)
*
|
2010-08-06 |
2015-11-04 |
国立大学法人山口大学 |
エストロゲン関連疾患の判定方法
|
|
EP2640727B1
(en)
|
2010-11-17 |
2015-05-13 |
Genentech, Inc. |
Alaninyl maytansinol antibody conjugates
|
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
JP6104257B2
(ja)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
|
PT2906253T
(pt)
|
2012-10-12 |
2018-11-05 |
Medimmune Ltd |
Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
|
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
EP2906297B1
(en)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
BR112015008238A2
(pt)
|
2012-10-12 |
2017-11-28 |
Adc Therapeutics Sarl |
conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
|
|
KR101995620B1
(ko)
|
2012-10-12 |
2019-07-03 |
에이디씨 테라퓨틱스 에스에이 |
피롤로벤조디아제핀-항체 컨주게이트
|
|
DK2906298T3
(en)
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
DK2839860T3
(da)
|
2012-10-12 |
2019-06-17 |
Medimmune Ltd |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
|
US8921307B2
(en)
|
2012-11-20 |
2014-12-30 |
Novartis Ag |
Synthetic linear apelin mimetics for the treatment of heart failure
|
|
AU2013366493B2
(en)
|
2012-12-21 |
2017-08-24 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US9567340B2
(en)
|
2012-12-21 |
2017-02-14 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
MX363787B
(es)
|
2013-03-13 |
2019-04-03 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de los mismos.
|
|
KR102066318B1
(ko)
|
2013-03-13 |
2020-01-14 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨쥬게이트
|
|
EP3024845A1
(en)
|
2013-07-25 |
2016-06-01 |
Novartis AG |
Cyclic polypeptides for the treatment of heart failure
|
|
WO2015013169A2
(en)
|
2013-07-25 |
2015-01-29 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
|
BR112016002829A2
(pt)
|
2013-08-12 |
2017-09-19 |
Genentech Inc |
Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
BR112016012410A2
(pt)
|
2013-12-16 |
2017-09-26 |
Genentech Inc |
conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
|
|
JP6980384B2
(ja)
|
2013-12-16 |
2021-12-15 |
ジェネンテック, インコーポレイテッド |
1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
|
|
UA118113C2
(uk)
|
2013-12-16 |
2018-11-26 |
Дженентек, Інк. |
Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
|
|
EP3134433A4
(en)
|
2014-04-25 |
2017-10-04 |
Libramen Naturals Inc. |
G-protein coupled receptor 22 transformed cell lines and uses therefor
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10149913B2
(en)
|
2014-09-12 |
2018-12-11 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP2017531620A
(ja)
|
2014-09-12 |
2017-10-26 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体及びコンジュゲート
|
|
JP2017533887A
(ja)
|
2014-09-17 |
2017-11-16 |
ジェネンテック, インコーポレイテッド |
ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
|
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
|
CA2969689A1
(en)
|
2014-12-03 |
2016-06-09 |
Genentech, Inc. |
Quaternary amine compounds and antibody-drug conjugates thereof
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
CR20180243A
(es)
|
2015-10-02 |
2018-07-31 |
Genentech Inc |
Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
JP6852065B2
(ja)
|
2015-10-20 |
2021-03-31 |
ジェネンテック, インコーポレイテッド |
カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
EP3416641A1
(en)
|
2016-02-16 |
2018-12-26 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Modulators of ccr9 for treating tumor resistance to immune responses
|
|
WO2017140803A1
(en)
|
2016-02-16 |
2017-08-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Modulators of tumor immune resistance for the treatment of cancer
|
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN109152843A
(zh)
|
2016-05-20 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
|
JP7043425B2
(ja)
|
2016-06-06 |
2022-03-29 |
ジェネンテック, インコーポレイテッド |
シルベストロール抗体-薬物コンジュゲート及び使用方法
|
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
RS61795B1
(sr)
|
2017-02-08 |
2021-06-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin antitela
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SMT202200490T1
(it)
|
2017-04-18 |
2023-01-13 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
KR102442736B1
(ko)
|
2017-06-14 |
2022-09-16 |
에이디씨 테라퓨틱스 에스에이 |
항-cd19 adc의 투여를 위한 투약량 체제
|
|
SI3668874T1
(sl)
|
2017-08-18 |
2022-04-29 |
Medimmune Limited |
Pirolobenzodiazepinski konjugati
|
|
ES3075078T3
(es)
|
2017-09-20 |
2026-07-27 |
Ph Pharma Co Ltd |
Análogos de tailanstatina
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
KR102907902B1
(ko)
|
2018-08-01 |
2026-01-02 |
난트퀘스트, 인크. |
면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
JP7232925B2
(ja)
|
2019-02-15 |
2023-03-03 |
ウーシー バイオロジクス アイルランド リミテッド |
改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
|
|
CN113631560B
(zh)
|
2019-03-15 |
2025-02-18 |
麦迪穆有限责任公司 |
氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
|
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
CN114848822A
(zh)
*
|
2022-06-01 |
2022-08-05 |
合肥工业大学 |
Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
|
|
WO2024044659A1
(en)
*
|
2022-08-24 |
2024-02-29 |
Tectonic Therapeutic, Inc. |
Constitutively active g protein-coupled receptor compositions and methods of use thereof
|
|
CN120417934A
(zh)
|
2022-12-23 |
2025-08-01 |
基因泰克公司 |
Cereblon降解剂缀合物及其用途
|
|
KR20260012304A
(ko)
|
2023-04-17 |
2026-01-26 |
피크 바이오, 인크. |
항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
|
|
WO2025207642A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Cxcr3 isoforms to improve recombinant receptor trafficking
|
|
TW202617186A
(zh)
|
2024-06-28 |
2026-05-01 |
美商飛爾富來生物公司 |
Bcl-xl降解劑抗體結合物及其用途
|
|
WO2026006688A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Degrader antibody conjugates and uses thereof
|